TY - JOUR T1 - The carbon footprint of respiratory treatments in Europe and Canada: An observational study from the CARBON programme JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.02760-2021 SP - 2102760 AU - Christer Janson AU - Ekaterina Maslova AU - Alexander Wilkinson AU - Erika Penz AU - Alberto Papi AU - Nigel Budgen AU - Claus F. Vogelmeier AU - Maciej Kupczyk AU - John Bell AU - Andrew Menzies-Gow Y1 - 2022/01/01 UR - http://erj.ersjournals.com/content/early/2022/06/09/13993003.02760-2021.abstract N2 - Climate change represents a global challenge and nations are increasingly looking to decarbonise their economies by developing roadmaps for reducing greenhouse gas (GHG) emissions in accordance with international treaties, such as the Paris Agreement [1].FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Christer Janson reports personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline PLC, Novartis and Teva outside the submitted work.Conflict of interest: Alexander Wilkinson is a member of the Montreal protocol Medical and Chemical Technical Options Committee and has made unpaid contributions to publications on the carbon footprint of inhalers and respiratory treatment which were sponsored by GlaxoSmithKline and AstraZeneca.Conflict of interest: Erika Penz has received honoraria and consulting fees from AstraZeneca, GlaxoSmithKline, Sanofi Genzyme, International Centre for Evidence-Based Medicine in Canada and Boehringer Ingelheim.Conflict of interest: Alberto Papi reports grants and personal fees from GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, Menarini and Sanofi/Regeneron; personal fees from Mundipharma, Zambon, Novartis, Edmond Pharma and Roche; and grants from Fondazione Maugeri and Fondazione Chiesi.Conflict of interest: Claus F. Vogelmeier has delivered presentations at symposia and/or served on scientific advisory boards sponsored by Aerogen, AstraZeneca, Boehringer Ingelheim, CSL Behring, Chiesi, GlaxoSmithKline, Grifols, Menarini, Novartis, Nuvaira and MedUpdate.Conflict of interest: Maciej Kupczyk reports grants from AstraZeneca and personal fees from AstraZeneca, Chiesi, GlaxoSmithKline, Novartis, Lekam, Alvogen, Emma, Nexter and Berlin Chemie.Conflict of interest: Ekaterina Maslova, Nigel Budgen and John Bell are employees of AstraZeneca.Conflict of interest: Andrew Menzies-Gow has attended advisory boards for GlaxoSmithKline, Novartis, AstraZeneca, Sanofi and Teva. He has received speaker fees from Novartis, AstraZeneca, Vectura, Teva and Roche. He has also participated in research with AstraZeneca and attended international conferences with Teva. He has consultancy agreements with AstraZeneca, Vectura and Sanofi. ER -